Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 154

Sort by

Sort Order Select

Journal Articles

Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study

Julio C. Chavez, Michael Dickinson, Javier Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Jacob Wulff, Chad M. Williams, Joshua Winters, Ioana Kloos, Hairong Xu, Sattva S. Neelapu

Blood (2025) 145 (20): 2303–2311.

https://doi.org/10.1182/blood.2024027347

Published: 2025

Includes: Supplemental data

Journal Articles

Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Jean-Marie Michot, Franck Morschhauser, Silvia Ferrari, Judit Mészáros Jørgensen, Loretta Nastoupil, Emmanuel Bachy, Michael Pourdehnad, Akshay Sudhindra, Alev Akyol, Bérengère de Moucheron, Soraya Carrancio, Jessica Voetsch, Xirong Zheng, Julio C. Chavez

Blood (2024) 144 (Supplement 1): 869.

https://doi.org/10.1182/blood-2024-203163

Published: 2024

Journal Articles

CD20xCD3 Bispecific Antibodies As Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL) - a Multicenter Retrospective Study

Ning Dong, Sushmita Khadka, Jose Sandoval-Sus, Carlos Silva Rondon, Ariel Perez, Tiba Al Sagheer, Madiha Iqbal, Juan Pablo Alderuccio, Cristian Rodriguez Arocho, Syeda Saba Kareem, Michael D. Jain, Julio C. Chavez

Blood (2024) 144 (Supplement 1): 3091.

https://doi.org/10.1182/blood-2024-203538

Published: 2024

Journal Articles

Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting

Katherine Tobon, Kylie Consalvo, Syeda Saba Kareem, Jeffrey E Lancet, Rami S. Komrokji, Javier Pinilla-Ibarz, David Sallman, Jennifer Eatrides, Alison R. Walker, Julio C. Chavez, Leidy Lismeris Isenalumhe, Bijal D Shah

Blood (2024) 144 (Supplement 1): 2820.

https://doi.org/10.1182/blood-2024-201486

Published: 2024

Journal Articles

5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 864.

https://doi.org/10.1182/blood-2024-194627

Published: 2024

Journal Articles

Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy

Jamila Mammadova, Yanina Pasikhova, Jongphil Kim, Junmin Whiting, Farhad Khimani, Michael D. Jain, Sayeef Mirza, Rawan Faramand, Julio C. Chavez, Bijal D Shah, Olga Klinkova, Aliyah Baluch, Jose L. Ochoa-Bayona, Fabiana Perna, Taiga Nishihori, Nelli Bejanyan, Frederick Locke, Aleksandr Lazaryan

Blood (2024) 144 (Supplement 1): 2103.

https://doi.org/10.1182/blood-2024-201878

Published: 2024

Journal Articles

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Blood (2024) 144 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2024-201730

Published: 2024

Journal Articles

Cell-Intrinsic and Immune-Mediated Effects in Lymphoma Patients Treated with Golcadomide and Associations with Treatment Outcome

Soraya Carrancio, Jessica Voetsch, Alberto Risueño, Carla Guarinos, Siddhesh Kulkarni, Mandeep Takhar, Matthew E. Stokes, Bérengère de Moucheron, Laura Furman, Julio C. Chavez, Jean-Marie Michot, Loretta Nastoupil, Daniel W. Pierce, Danielle Greenawalt, Michael Pourdehnad

Blood (2024) 144 (Supplement 1): 3104.

https://doi.org/10.1182/blood-2024-203139

Published: 2024

Journal Articles

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility and Preliminary Outcomes from a Single-Arm Pilot Study

Nathan Parker, Morgan Bean, Mart Theodore De Vera, Rachel Carmella, Jessica McCoy, Salvatore Corallo, Luis Cuadrado Delgado, Meghan Menges, Omar Castaneda, Julio C. Chavez, Rawan Faramand, Michael D. Jain, Heather S.L. Jim, Aleksandr Lazaryan, Sayeef Mirza, Laura B. Oswald, Bijal D Shah, Frederick L. Locke, Ciara Louise Freeman

Blood (2024) 144 (Supplement 1): 7224.

https://doi.org/10.1182/blood-2024-208557

Published: 2024

Journal Articles

Incidence of Secondary Malignancy after Treatment with Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cell Therapies

Can Jones, Amneh A Fares, Diana Martinez, Jennifer M Logue, Carlos Silva Rondon, Fernando Vargas Madueno, Nina Nguyen, Hugo Francisco Fernandez, Julio C. Chavez, Jose Sandoval-Sus

Blood (2024) 144 (Supplement 1): 7241.

https://doi.org/10.1182/blood-2024-206293

Published: 2024

Journal Articles

The Real-World Safety and Tolerability of Pirtobrutinib Among Patients with B Cell Lymphomas; A Single Center Experience

Mohammad Ammad Ud Din, Katherine Tobon, Julio C. Chavez, Lisa Nodzon, Hayder Saeed, Sameh Gaballa, Ning Dong, Leidy Lismeris Isenalumhe, Celeste M. Bello, Ariel Grajales-Cruz, Kenneth H. Shain, Lubomir Sokol, Bijal D Shah, Javier Pinilla-Ibarz

Blood (2024) 144 (Supplement 1): 6778.

https://doi.org/10.1182/blood-2024-208769

Published: 2024

Journal Articles

Impact of Neurological and Psychiatric Comorbidities on Toxicity and Outcomes of Patients with DLBCL Who Receive Axicabtagene Ciloleucel

Rebecca Albuquerque, Anna Shamis, Athanasios Tsalatsanis, Ambuj Kumar, Zain Ahmad, Hasiq Ovais, Aleksandr Lazaryan, Farhad Khimani, Rawan Faramand, Ciara Louise Freeman, Bijal D Shah, Sameh Gaballa, Julio C. Chavez, Fabiana Perna, Jose L. Ochoa-Bayona, Frederick L. Locke, Michael D. Jain, Taiga Nishihori, Abu-Sayeef Mirza

Blood (2024) 144 (Supplement 1): 7734.

https://doi.org/10.1182/blood-2024-208905

Published: 2024

Journal Articles

Impact of Autoimmune Disease on Toxicity and Outcomes after Axicabtagene Ciloleucel in Patients with Diffuse Large B Cell Lymphoma

Anna Shamis, Rebecca Albuquerque, Athanasios Tsalatsanis, Ambuj Kumar, Zain Ahmad, Hasiq Ovais, Aleksandr Lazaryan, Farhad Khimani, Rawan Faramand, Ciara Louise Freeman, Bijal D Shah, Sameh Gaballa, Julio C. Chavez, Fabiana Perna, Jose L. Ochoa-Bayona, Frederick Locke, Michael D. Jain, Taiga Nishihori, Abu-Sayeef Mirza

Blood (2024) 144 (Supplement 1): 7733.

https://doi.org/10.1182/blood-2024-208743

Published: 2024

Journal Articles

Identifying the Role of Endoplasmic Reticulum Stress in CLL T-Cell Dysfunction

Wael Gamal, Melanie Mediavilla Varela, Angimar Uriepero Palma, Mohammad Ammad Ud Din, Julio C. Chavez, Eva Sahakian, Paulo C. Rodriguez, Javier Pinilla-Ibarz

Blood (2024) 144 (Supplement 1): 1848.

https://doi.org/10.1182/blood-2024-210608

Published: 2024

Journal Articles

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Juan Pablo Alderuccio, Jahanzaib Khwaja, Sunwoo Han, Paola Ghione, Imran A. Nizamuddin, Aditi Saha, Ning Dong, Yucai Wang, Hua-Jay J Cherng, Seda S. Tolu, Nina Wagner-Johnston, Adam J. Olszewski, Natalie Grover, Jean L. Koff, Amrita Desai, Praveen Ramakrishnan Geethakumari, Tamara K Moyo, Jose Sandoval-Sus, Narendranath Epperla, Danielle S Wallace, Manali Kamdar, Alexey Danilov, Han W. Tun, Javier Munoz, Mayur S. Narkhede, Joanna M. Rhodes, Anca Prica, Andrea Kuhnl, Adrian Maraj, Jessica Okosun, Jeffery Smith, Wendy Osborne, Victoria Calvert, Dima el-Sharkawi, Ammar Hilali, Graham P. Collins, Kim Linton, Nagah Elmusharaf, Anna Santarsieri, Farheen Karim, Thomas Ollila, Sarah Monick, Iris Margalit Trutzer, Nilanjan Ghosh, Jones Can, Amy Ayers, Jacopo Calabrese De Feo, John Sharp, Rachel Treitman, Avyakta Kallam, Izel Okcu, Vismay Deshani, Firas Baidoun, Chathuri Abeyakoon, William Hann, Aisling Barrett, Brad Kahl, Julio C. Chavez, Kate Cwynarski

Blood (2024) 144 (Supplement 1): 571.

https://doi.org/10.1182/blood-2024-199781

Published: 2024

Journal Articles

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2024) 144 (Supplement 1): 989.

https://doi.org/10.1182/blood-2024-194581

Published: 2024

Journal Articles

Clinical Characteristics and Outcomes of Patients with MYD88 Positive Waldenström Macroglobulinemia: A Single Center Retrospective Analysis

Shrinjaya B Thapa, David Kaldas, Jose Laborde, Shrikar Modukuri, Filip Ionescu, Brandon Blue, Julio C. Chavez, Melissa Alsina, Celeste M. Bello, Javier Pinilla-Ibarz, Kenneth H. Shain, Rachid C. Baz, Ariel Grajales-Cruz

Blood (2024) 144 (Supplement 1): 3021.

https://doi.org/10.1182/blood-2024-208701

Published: 2024

Journal Articles

Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy

Blood (2024) 144 (Supplement 1): 5099.

https://doi.org/10.1182/blood-2024-198742

Published: 2024

Journal Articles

Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study

Julio C. Chavez, Guilherme Fleury Perini, Loretta Nastoupil, Judit Mészáros Joergensen, Pierre Bories, Bijou Fontanet, Pier Luigi Zinzani, Javier Munoz, Daniel Morillo Giles, Cecilia Carpio, Abel Costa, Won Seog Kim, Parth Rao, Bérengère de Moucheron, Yang Gang, Carla Guarinos, Akshay Sudhindra, Michael Pourdehnad, Jean-Marie Michot

Blood (2024) 144 (Supplement 1): 3018.

https://doi.org/10.1182/blood-2024-203131

Published: 2024

Journal Articles

A Phase I Study of Duvelisib in Combination with Oral Azacitidine (BMS-986345) in Mature T Cell Lymphoma

Hayder Saeed, Melanie Mediavilla Varela, Eva Sahakian, Mahrukh Naqvi, Qiangxing Mo, Ling Zhang, Rikesh Makanji, Yumeng Zhang, Ning Dong, Leidy Lismeris Isenalumhe, Sameh Gaballa, Julio C. Chavez, Bijal D Shah, Celeste M. Bello, Lubomir Sokol, Javier Pinilla-Ibarz

Blood (2024) 144 (Supplement 1): 3065.

https://doi.org/10.1182/blood-2024-205173

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study

Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

CD20xCD3 Bispecific Antibodies As Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL) - a Multicenter Retrospective Study

Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting

5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Cell-Intrinsic and Immune-Mediated Effects in Lymphoma Patients Treated with Golcadomide and Associations with Treatment Outcome

Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility and Preliminary Outcomes from a Single-Arm Pilot Study

Incidence of Secondary Malignancy after Treatment with Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cell Therapies

The Real-World Safety and Tolerability of Pirtobrutinib Among Patients with B Cell Lymphomas; A Single Center Experience

Impact of Neurological and Psychiatric Comorbidities on Toxicity and Outcomes of Patients with DLBCL Who Receive Axicabtagene Ciloleucel

Impact of Autoimmune Disease on Toxicity and Outcomes after Axicabtagene Ciloleucel in Patients with Diffuse Large B Cell Lymphoma

Identifying the Role of Endoplasmic Reticulum Stress in CLL T-Cell Dysfunction

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Clinical Characteristics and Outcomes of Patients with MYD88 Positive Waldenström Macroglobulinemia: A Single Center Retrospective Analysis

Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy

Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study

A Phase I Study of Duvelisib in Combination with Oral Azacitidine (BMS-986345) in Mature T Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only